Press Release: Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector

Press Release: Sanofi launches 2026 global employee stock purchase plan

Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease

Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi

Press Release: Q1 2026: double-digit sales and business EPS growth

Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children

Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US

Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease

Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

Press release: Availability of the Q1 2026 aide-mémoire

Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease

Press Release: Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director

Press Release: Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report

Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease